(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number
WO 01/76575 A2

(51) International Patent Classification[7]: A61K 31/00

(21) International Application Number: PCT/GB01/01606

(22) International Filing Date: 9 April 2001 (09.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0008660.3 7 April 2000 (07.04.2000) GB

(71) Applicant *(for all designated States except US)*: **ARAKIS LTD.** [GB/GB]; The Coach House, 88 Long Lane, Willingham, Cambridge CB4 5LD (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BANNISTER, Robin, Mark** [GB/GB]; Arakis Ltd., Babraham Hall, Babraham, Cambridge CB2 4AT (GB). **RICHARDS, Andrew, John, McGlashan** [GB/GB]; The Limes, 88 Long Lane, Willingham, Cambridge CB4 5LD (GB). **GILBERT, Julian, Clive** [GB/GB]; Arakis Ltd., Babraham Hall, Babraham, Cambridge CB2 4AT (GB). **MORTON, David, A., V.** [GB/GB]; Vectura Limited, Centre for Drug Formulation Studies, University of Bath, Claverton Down, Bath BA2 7AY (GB). **STANIFORTH, John** [GB/GB]; Vectura Limited, Centre for Drug Formulation Studies, University of Bath, Claverton Down, Bath BA2 7AY (GB).

(74) Agent: **GILL JENNINGS & EVERY**; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/76575 A2

(54) Title: THE TREATMENT OF RESPIRATORY DISEASES

(57) Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.

THE TREATMENT OF RESPIRATORY DISEASES

Field of the Invention

This invention relates to the treatment of respiratory diseases.

Background of the Invention

Glycopyrrolate has been known for many years as an effective antimuscarinic agent. It has been used in several indications and been delivered by a number of different routes. It is currently used as an injectable primed to reduce secretions during anaesthesia and also as an oral product for treating gastric ulcers. One of the first descriptions of its use in airway disease was in 1984 where it was demonstrated to have a significant effect upon bronchodilation. Since then a number of studies have confirmed its potential utility.

Schroeckenstein *et al.*, J. Allergy Clin. Immunol., 1988; 82(1): 115-119, discloses the use of glycopyrrolate in an aerosol formulation for treating asthma. A single administration of the metered-dose glycopyrrolate aerosol achieved bronchodilation over a 12 hour period.

Leckie *et al.*, Exp. Opin. Invest. Drugs, 2000; 9(1): 3-23, is a general review of therapies for chronic obstructive pulmonary disease (COPD). Glycopyrrolate is mentioned as a possible drug treatment. However, there is no reference to its level of activity or to the duration at which it exerts its therapeutic effect.

Skorodin, Arch Intern. Med, 1993; 153: 814-828, discloses the use of glycopyrrolate in an aerosol formulation for the treatment of asthma and COPD. It is stated that, in general, the quaternary ammonium anticholinergic compounds have a duration of action of 4 to 12 hours. A dose of between 0.2 to 1.0 mg of glycopyrrolate is recommended at 6 to 12 hour intervals.

Walker *et al.*, Chest, 1987; 91(1): 49-51, also discloses the effect of inhaled glycopyrrolate as an asthma treatment. Again, the duration of effective treatment is shown to be up to 12 hours, although up to 8 hours appears to be maximal.

WO-A-97/39758 discloses pharmaceutical compositions for treating respiratory inflammation containing the antioxidant tyloxapol. Page 23 refers to

the addition of glycopyrrolate as an additional component in solution. There is no reference to the duration of activity of the glycopyrrolate, and the proposed effective dose (200-1000 µg) is similar to that described in the prior art above.

With this background, it is surprising to find that no glycopyrrolate formulation has been developed or registered for the treatment of airway disease. There are a number of possible reasons for this, and may include fears concerning systemic exposure and the drug binding at muscarinic receptors other than in the airways. This could result in both central and peripheral side-effects in patient populations that are already disposed to these complications. Such complications could be cardiovascular, ocular, mucosal or a predisposition to dizziness or fainting.

Summary of the Invention

An object behind the present invention has been to develop an inhaled formulation which is a potent, effective, long-acting bronchodilator for the treatment of respiratory disease, in particular COPD. The pharmacodynamic and pharmacokinetic effects of the drug from the inhaled route will be controlled within a suitable formulation to ensure that the product is able to produce its effect following, preferably, once daily dosing.

According to a first aspect of the invention, a pharmaceutical composition for pulmonary delivery comprises an antimuscarinic agent that exerts a pharmacological effect over a period less than 12 hours, in a controlled release formulation, wherein, on administration, the formulation permits the agent to exert its pharmacological effect over a period greater than 12 hours. Glycopyrrolate is the preferred agent.

As this composition is able to exert its therapeutic effect over a prolonged period, the patient will benefit from relief of symptoms for a longer period than with conventional antimuscarinic treatments. Furthermore, the patient may only require a once-a-day treatment regimen, and as this will usually avoid missed treatments, better compliance is expected. In addition, providing the agent in a controlled release formulation ensures that a lower initial peak of activity is achieved, which may result in reduced side effects associated with anticholinergic activity, for example dry mouth.

According to a second aspect of the invention, a particulate composition comprises discrete microparticles, each comprising an antimuscarinic agent held within a hydrophobic matrix material.

Formulating the antimuscarinic agent this way allows controlled release of the therapeutic so that the pharmacological effect is achieved over a period of time greater than 12 hours.

According to a third aspect of the invention, the antimuscarinic is used in the manufacture of a medicament suitable for inhalation, for the treatment of a disease of the airways, the medicament being formulated so that one unit dose enables the agent to exert its pharmacological effect over a period greater than 12 hours.

According to a fourth aspect of the invention, a dry powder inhaler comprises a unit dose of an antimuscarinic agent in a controlled release formulation that permits the agent to exert its pharmacological effect over a period greater than 12 hours.

In each of the above aspects, the formulation is optimised for absorption and retention in the airways such that efficacy is maintained with systemic levels of drug at a concentration that does not cause significant side-effects in patients susceptible to muscarinic side-effects.

Description of the Drawing

The accompanying drawing illustrates the invention, where:

Figure 1 illustrates the concentration of glycopyrrolate released over time, in a controlled release formulation.

Description of the Invention

The present invention relates to all antimuscarinic agents that normally exert their pharmacological effect over a period less than 12 hours. Glycopyrrolate is preferred, and the following description is in the context of glycopyrrolate formulations.

By means of the invention, glycopyrrolate can be used to treat airway disease, particularly COPD, asthma or cystic fibrosis. This may be effective in general. Further, particularly given that patients having such conditions often suffer from complications or are undergoing other therapies, this invention has

utility in treating certain patient populations, e.g. those which may have sensitivity arising from cardiovascular, ocular or mucosal complications.

The reference to the "pharmacological effect" relates to the ability of the agent to relieve the symptoms of the airway disorder. This may be a measure of the FEV_1 levels, which are elevated in the presence of the agent when compared to that obtained in the absence of the treatment.

Conventional formulation technology may be used to achieve the controlled release composition. The important aspect is that the composition should have a duration of action greater than 12 hours, preferably more than 15 hours or 18 hours and most preferably more than 20 hours. This can be measured by techniques known to the skilled person, as shown below.

The controlled release formulations of glycopyrrolate are to be provided in a form suitable for delivery by inhalation. Devices and formulations suitable for delivery by inhalation are known to the skilled person. The composition may be prepared for delivery as an aerosol in a liquid propellant, for example for use in a pressurised metered dose inhaler (PMDI's). Propellants suitable for use in a PMDI are known to the skilled person, and include CFC-12, HFA-134a, HFA-227, HCFC-22 (difluorochloromethane), HFA-152 (difluoroethane and isobutane).

In a preferred embodiment of the invention, the compositions are in a dry powder form, for delivery using a dry powder inhaler (DPI). Dry powder inhalers are known. The dry powders for use in the inhalers will usually have a mass medium aerodynamic diameter of less than 30 μm, preferably less than 20 μm and more preferably less than 10 μm. Microparticles having aerodynamic diameters in the range of 5 to 0.5 μm will generally be deposited in the respiratory bronchioles, whereas smaller particles having aerodynamic diameters in the range of 2 to 0.05 μm are likely to be deposited in the alveoli.

Having the glycopyrrolate in a controlled release formulation means that fewer doses are required, and subsequently inhalers may be provided with treatment packages that supply the glycopyrrolate over an extended number of treatment days compared to packages that have a similar number of doses per pack, but from which two or three doses are required each day.

In a preferred embodiment of the invention, the glycopyrrolate is formulated with a hydrophobic matrix material to form microparticles suitable for inhalation. The microparticles may be within the ranges specified above. Any pharmaceutically acceptable hydrophobic material may be used to formulate the microparticles, and suitable materials will be apparent to the skilled person. Preferred hydrophobic materials include solid state fatty acids such as oleic acid, lauric acid, palmitic acid, stearic acid, erucic acid, behenic acid, or derivatives (such as esters and salts) thereof. Specific examples of such materials include phosphatidylcholines, phosphatidylglycerols and other examples of natural and synthetic lung surfactants. Particularly preferred materials include metal stearates, in particular magnesium stearate, which has been approved for delivery via the lung.

The hydrophobic materials are resistant to immediate dissolution on administration, but are broken down over time to release the glycopyrrolate component.

The microparticles may also be formulated with additional excipients to aid delivery and release. For example, in the context of dry powder formulations, the microparticles may be formulated with additional large carrier particles which aid the flow from the dry powder inhaler into the lung. Large carrier particles are known, and include lactose particles having a mass medium aerodynamic diameter of greater than 90 μm. Alternatively, the hydrophobic microparticles may be dispersed within a carrier material. For example, the hydrophobic microparticles may be dispersed within a polysaccharide matrix, with the overall composition formulated as microparticles for direct delivery to the lung. The polysaccharide acts as a further barrier to the immediate release of the glycopyrrolate component. This may further aid the controlled release process. Suitable carrier materials will be apparent to the skilled person and include any pharmaceutically acceptable insoluble or soluble material, including polysaccharides. An example of a suitable polysaccharide is xantham gum.

The compositions may also comprise additional therapeutic agents, either as separate components, i.e. as separate microparticles, or combined with the glycopyrrolate in the microparticles. In one embodiment, a therapeutic

composition comprises the microparticles according to the invention, together with microparticles consisting of the glycopyrrolate, i.e. without any hydrophobic matrix material. This provides a composition that has a fast-acting component and a controlled-release component, and may provide effective relief quickly to a patient, together with a longer lasting effect. The fast-acting glycopyrrolate may be provided as additional microparticles, or may be dispersed, together with the hydrophobic microparticles, within a particle. For example, polysaccharide particles can be formulated with hydrophobic microparticles and fast-acting glycopyrrolate dispersed therein.

Controlled release formulations may be tested by methods known to those skilled in the art. Testing the formulations for release of glycopyrrolate in water may be used. Controlled release formulations will usually release 50% of the glycopyrrolate by dissolution in water over a period greater than 10 minutes, preferably greater than 20 minutes and most preferably greater than 30 minutes. During administration, the controlled release formulation may release the glycopyrrolate over a period greater than 12 hours, preferably 15 hours, more preferably 20 hours.

Any suitable pharmaceutically effective drug which is used for the treatment of a respiratory disease may also be co-administered with the glycopyrrolate compositions of the invention. For example, β_2-agonists, e.g. salbutamol, salmeterol and formetoral, may be formulated for co-administration with the glycopyrrolate compositions. Additional anti-muscarinic compounds may also be co-administered. For example, ipratropium (e.g. ipratropium bromide) or tiotropium may be administered. Isomers, salt forms or counterion formulations of the antimuscarinic compounds are all within the scope of the present invention. These may be in their natural form or in a controlled release formulation. The natural form is preferred.

Additional therapeutics including steroids may also be co-administered. Examples of suitable steroids include beclomethasone, dipropionate and fluticasone. Other suitable therapeutics include mucolytics, matrix metalloproteinase inhibitors (MMPi's), leukotrienes, antibiotics, antineoplastics,

peptides, vaccines, antitussives, nicotine, PDE4 inhibitors, elastase inhibitors and sodium cromoglycate.

Combination therapy may provide the maximal effect on FEV-1 and vital capacity. Co-administration of other drugs together with the slow release glycopyrrolate may also result in less side effects compared to co-administration with the conventional glycopyrrolate formulations, as there may be less contra-indications due to the late onset of activity of the glycopyrrolate.

Glycopyrrolate has two stereogenic centres and hence exists in four isomeric forms. Each individual isomer may be delivered to optimise the efficacious effect of the drug, and reduce systemic exposure to those isomers that are responsible for systemic side-effects.

A formulation of active isomers may be used, in which the ratio of isomers is 1:1, or less than 1:1. Alternatively, the formulation of active isomers is non-racemic, or the formulation ensures that the of active isomers are delivered at different rates.

Salt forms or counterion formulations of glycopyrrolate are within the scope of the present invention, e.g. glycopyrrolate bromide.

It is desirable that a formulation should be used, such that peak plasma levels related to systemic exposure are lower than previously, e.g. because of controlled release to give substantially constant plasma levels.

Compositions according to the invention may be produced using conventional formulation techniques. In particular, spray-drying may be used to produce the microparticles comprising the glycopyrrolate dispersed or suspended within a material that provides the controlled release properties.

The process of milling, for example, jet milling, may also be used to formulate the therapeutic composition. The manufacture of fine particles by milling can be achieved using conventional techniques. The term "milling" is used herein to refer to any mechanical process which applies sufficient force to the particles of active material to break or grind the particles down into fine particles. A wide range of milling devices and conditions are suitable for use in the production of the compositions of the inventions. The selection of appropriate milling conditions, for example, intensity of milling and duration, to

provide the required degree of force will be within the ability of the skilled person. Ball milling is a preferred method. Alternatively, a high pressure homogeniser may be used in which a fluid containing the particles is forced through a valve at high pressure producing conditions of high sheer and turbulence. Sheer forces on the particles, impacts between the particles and machine surfaces or other particles, and cavitation due to acceleration of the fluid may all contribute to the fracture of the particles. Suitable homogenisers include the EmulsiFlex high pressure homogeniser, the Niro Soavi high pressure homogeniser and the Microfluidics Microfluidiser. The milling process can be used to provide the microparticles with mass median aerodynamic diameters as specified above. Milling the glycopyrrolate with a hydrophobic material is preferred, as stated above.

If it is required, the microparticles produced by the milling step can then be formulated with an additional excipient to produce particles with the hydrophobic microparticles dispersed therein. This may be achieved by a spray-drying process, e.g. co-spray-drying. In this embodiment, the hydrophobic microparticles are suspended in a solvent and co-spray-dried with a solution or suspension of the additional excipient. The spray-drying process will produce microparticles of a desired size which will comprise the hydrophobic microparticles dispersed therein. Preferred additional excipients include polysaccharides. Additional pharmaceutically effective excipients may also be used.

The amount of the active agent to be administered will be determined by the usual factors such as the nature and severity of the disease, the condition of the patient and the potency of the agent itself. These factors can readily be determined by the skilled man. The controlled release formulation is used to sustain the bronchodilatory effect over a prolonged period and raise the FEV levels. Following initial dosing, and subsequent doses, the FEV_1 level may be maintained at a level higher than that prior to the start of the therapy. It is desirable to provide sufficient active agent so that one unit dose will enable the glycopyrrolate to exert its pharmacological effect over a period greater than 12 hours, preferably greater than 15 or 18 hours, and more preferably greater than

20 hours. The amount of glycopyrrolate released over this period will be sufficient to provide effective relief (bronchodilation) of the respiratory disease, over this period. The measurement of bronchodilation may be carried out by techniques known to the skilled person, including spirometry. This may be used to measure the FEV_1 over the administration period. It is desirable to achieve a FEV_1 value that is greater than 10% of the predicted normal value, preferably greater than 20% and most preferably greater than 30%, over the administration period. The amount of glycopyrrolate in one unit dose may be similar to that disclosed in the prior art, e.g. 0.02 - 5 mg, preferably less than 2 mg, most preferably less than or about 1 mg. Larger or smaller doses may also be provided, for example, less than 100 µg. In the context of the microparticles, the glycopyrrolate may be present in, for example, greater than 20% by weight, preferably greater than 40% by weight, and more preferably greater than 60% by weight.

The compositions of the invention may be used to treat a disease of the airways, including asthma, cystic fibrosis, COPD or lung carcinoma associated with concomitant COPD (see co-pending application GB-A-0027798.8).

The following Example illustrations the invention.

Example

A mixture of micronised glycopyrrolate and magnesium stearate in the ratio 75:25 by mass (total mass of approximately 1 g) was placed in a ball mill on top of 100 g of 2 mm diameter stainless steel balls. The mill volume was approximately 58.8 ml. 5 ml of cyclohexane was added to wet the mixture. The mill was sealed and secured in a Retsch S100 centrifuge. Centrification was then carried out at 500 rpm for 240 minutes in total. Small samples (approximately 5-10 mg) of wet powder were removed from the mill every 60 minutes. The samples were dried in an oven at 37°C under vacuum, prior to using the samples in a dissolution test.

The dissolution test was conducted with approximately 1 mg of micronised glycopyrrolate and approximately 1 mg of a ball milled glycopyrrolate/magnesium stearate mixture sampled after 60 minutes. A 195 ml reservoir was used in the dissolution test. The reservoir was filled with water and contained a sampling inlet

port and a sampling outlet port. A sintered disk of approximately 50 mm diameter and 3 mm depth was placed in an opening on top of the reservoir, in contact with the water. A known mass (about 1 mg) of the sample to be tested was dropped onto the sinter and a timer started. At various times, 1 ml samples were removed from the reservoir and immediately replaced with 1 ml of water to maintain the volume in the system. The samples were analysed in a Cecil Aquarius CE7200 ultraviolet spectrophotometer at a wavelength of 200 nm. The concentration of the samples was calculated with a previously prepared calibration graph and the concentration versus time was plotted. To establish the base line diffusion characteristics of the system, a 1 ml solution containing 1 mg of glycopyrrolate was added to the system and the samples taken as above. The results are shown in Figure 1.

Figure 1 shows that the sample containing only glycopyrrolate exhibited a quick release of the glycopyrrolate into the reservoir, with the first time point at 5 minutes showing a concentration of greater than 10 mg/l. In contrast, the glycopyrrolate/magnesium stearate composition showed delayed release properties, with a concentration at 5 minutes of approximately 3.7 mg/l. The maximum concentration is achieved after 40 minutes in contrast to that of glycopyrrolate only, which achieves the maximum concentration at only 10 minutes.

CLAIMS

1. A composition for pulmonary delivery, comprising an antimuscarinic agent that exerts its pharmacological effect over a period less than 12 hours, in a controlled release formulation that permits the antimuscarinic agent to exert its pharmacological effect over a period greater than 12 hours.

2. A composition according to claim 1, wherein the antimuscarinic agent is glycopyrrolate.

3. A composition according to claim 1 or claim 2, comprising discrete microparticles, each comprising the antimuscarinic agent held within a hydrophobic matrix material.

4. A composition according to claim 3, wherein the hydrophobic matrix comprises magnesium stearate.

5. A composition according to claim 3 or claim 4, wherein the microparticles are from 0.1 μm to 10 μm in diameter.

6. A composition according to any of claims 3 to 5, wherein the microparticles are dispersed or suspended within particles of a carrier material.

7. A composition according to claim 6, wherein the carrier material is a polysaccharide.

8. A composition according to any preceding claim, further comprising a β_2-agonist.

9. A composition according to any of claims 1 to 7, further comprising an additional antimuscarinic agent.

10. A composition according to claim 10, wherein the additional agent is ipratropium or tiotropium.

11. A composition according to any preceding claim, further comprising microparticles consisting of glycopyrrolate.

12. A composition according to any of claims 1 to 7, further comprising a therapeutic selected from steroids, mucolytics, MMPi's, Leukotrienes, antibiotics, antineoplastics, peptides, vaccines, antitussives, nicotine, sodium cromoglycate, PDE4 inhibitors and elastase inhibitors.

13. A composition according to any preceding claim, wherein the controlled release formulation permits the agent to exert its pharmacological effect over a period greater than 15 hours.

14. A composition according to any preceding claim, wherein the antimuscarinic agent is present in an amount of less than 5 mg.

15. A composition according to claim 14, wherein the antimuscarinic agent is present in an amount of less than 1 mg.

16. Use of an antimuscarinic agent as defined in claim 1 or claim 2, in the manufacture of a medicament suitable for inhalation, for the treatment of a disease of the airways, wherein one unit dose of the medicament enables the antimuscarinic agent to exert its pharmacological effect over a period greater than 12 hours.

17. Use according to claim 16, wherein the medicament comprises a composition according to any of claims 1 to 15.

18. Use according to claim 16 or claim 17, wherein the disease is asthma.

19. Use according to claim 16 or claim 17, wherein the disease is cystic fibrosis.

20. Use according to claim 16 or claim 17, wherein the disease is chronic obstructive pulmonary disease (COPD).

21. Use according to claim 16 or claim 17, wherein the disease is lung carcinoma associated with concomitant COPD.

22. A method for the treatment of a pulmonary disorder, comprising administering an antimuscarinic agent in a controlled release formulation, such that, on administration, the FEV_1 level is elevated and does not return to its pretreatment level during subsequent administrations at up to 24 hours.

23. A dry powder inhaler comprising a unit dosage of a composition according to any of claims 1 to 15.

24. A dry powder inhaler comprising a unit dosage of an antimuscarinic agent as defined in claim 1 or claim 2, or in a controlled release formulation that permits the agent to exert its pharmacological effect over a period greater than 12 hours.

25. A process for the manufacture of an antimuscarinic agent in a controlled release formulation, comprising dissolving or suspending the agent in a hydrophobic material, and drying the material to form microparticles suitable for pulmonary delivery.

26. A process according to claim 25, wherein the agent is glycopyrrolate.

27. A process according to claim 25 or claim 26, wherein the agent and hydrophobic material are admixed and dried by spray-drying.

28. A process according to claim 25 or claim 26, wherein the agent and hydrophobic material are admixed and dried by milling.

29. A process according to any of claims 25 to 28, wherein the hydrophobic material comprises magnesium stearate.

30. A process according to any of claims 25 to 29, wherein the microparticles are further suspended in a carrier material, which is then dried to form microparticles for pulmonary delivery.

31. A process according to claim 30, wherein the carrier material is a polysaccharide.


unprocessed
1mg/ml solution
60 min processed/MgSt
concentration (mg/l)
16.000
14.000
12.000
10.000
8.000
6.000
4.000
2.000
0.000
0
10
20
30
40
50
60
70
80
90
100
time (min)

Figure 1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number
WO 01/76575 A3

(51) International Patent Classification[7]: A61K 31/40

(21) International Application Number: PCT/GB01/01606

(22) International Filing Date: 9 April 2001 (09.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0008660.3 7 April 2000 (07.04.2000) GB

(71) Applicant *(for all designated States except US)*: **ARAKIS LTD.** [GB/GB]; Babraham Hall, Babraham, Cambridge, CB2 4AT (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BANNISTER, Robin, Mark** [GB/GB]; Arakis Ltd., Babraham Hall, Babraham, Cambridge CB2 4AT (GB). **RICHARDS, Andrew, John, McGlashan** [GB/GB]; The Limes, 88 Long Lane, Willingham, Cambridge CB4 5LD (GB). **GILBERT, Julian, Clive** [GB/GB]; Arakis Ltd., Babraham Hall, Babraham, Cambridge CB2 4AT (GB). **MORTON, David, A., V.** [GB/GB]; Vectura Limited, Centre for Drug Formulation Studies, University of Bath, Claverton Down, Bath BA2 7AY (GB). **STANIFORTH, John** [GB/GB]; Vectura Limited, Centre for Drug Formulation Studies, University of Bath, Claverton Down, Bath BA2 7AY (GB).

(74) Agent: **GILL JENNINGS & EVERY**; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

(88) Date of publication of the international search report:
28 March 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/76575 A3

(54) Title: THE TREATMENT OF RESPIRATORY DISEASES

(57) Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.

INTERNATIONAL SEARCH REPORT

Inter ·nal Application No
PCT/GB 01/01606

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EMBASE, BIOSIS, EPO-Internal, CHEM ABS Data, MEDLINE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 00 28979 A (SKYEPHARMA AG ;MUELLER WALZ RUDI (DE); KELLER MANFRED (DE)) 25 May 2000 (2000-05-25) abstract page 11, line 4 -page 12, line 2; claims 1-12,16,18-26 page 12, line 17 -page 13, line 10 page 13, line 25 -page 14, line 13; claims 8,9,25; example 8 . --- -/--	1-17, 23-31

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
28 December 2001	07/01/2002

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	A. Jakobs

1

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCHROECKENSTEIN D C ET AL: "TWELVE-HOUR BRONCHODILATION IN ASTHMA WITH A SINGLE AEROSOL DOSE OF THE ANTICHOLINERGIC COMPOUND GLYCOPYRROLATE" JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 82, no. 1, 1988, pages 115-119, XP000979862 ISSN: 0091-6749 abstract; table 2 page 117, column 1, paragraph 1 -column 2, paragraph 3 ---	1-7, 13-18, 20-24
X	WALKER F B ET AL: "PROLONGED EFFECT OF INHALED GLYCOPYRROLATE IN ASTHMA" CHEST, vol. 91, no. 1, 1987, pages 49-51, XP000979963 ISSN: 0012-3692 abstract ---	1-7, 13-18, 20-24
X	SKORODIN M.S.: "Pharmacotherapy for asthma and chronic obstructive pulmonary disease: Current thinking, practices, and controversies." ARCHIVES OF INTERNAL MEDICINE, (1993) 153/7 (814-824)., XP000979854 abstract page 818, column 1, paragraph 4 -page 819, column 3, line 1; figure 5; table 2 ---	1-18, 20-24
X	ZIMENT I.: "Pharmacologic therapy of obstrutive airway disease." CLINICS IN CHEST MEDICINE, (1990) 11/3 (461-486+VI)., XP000981338 page 461, column 1, paragraph 1 page 470, column 1, paragraph 3 -page 471, column 1, paragraph 1; table 2 ---	1-18, 20-24
X	TZELEPIS G ET AL: "Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease." EUROPEAN RESPIRATORY JOURNAL, vol. 9, no. 8, 1996, pages 100-103, XP000979863 ISSN: 0903-1936 abstract page 100, column 1, paragraph 1 page 102, column 1, paragraph 2 --- -/--	1-8, 12-18, 20-24

1

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X	BOYARS M.C.: "COPD in the ambulatory elderly: Management update." GERIATRICS, (1988) 43/6 (29-40)., XP000979857 abstract page 35, column 1, paragraphs 2,3 ---	1-8, 12-18, 20-24
X	LECKIE M J ET AL: "NOVEL THERAPY FOR COPD" EXPERT OPINION ON INVESTIGATIONAL DRUGS,GB,ASHLEY PUBLICATIONS LTD., LONDON, vol. 9, no. 1, 2000, pages 3-23, XP000911149 ISSN: 1354-3784 abstract page 3, paragraph 2 -page 4, paragraph 5; table 1 page 8, column 2, paragraph 2 -page 9, column 2, paragraph 1 ---	1-8, 12-18, 20-24
X	US 5 612 053 A (BAICHWAL ANAND ET AL) 18 March 1997 (1997-03-18) abstract column 3, line 1-40 column 10, line 1-14 ---	1-3,5-7
X	HOWDER C.L.: "Antimuscarinic and.beta.2-adrenoceptor bronchodilators in obstructive airways disease." RESPIRATORY CARE, (1993) 38/12 (1364-1388). , XP001051501 abstract page 1366, column 1, paragraph 2 -page 1367, column 2, paragraph 2; figures 3,4; tables 1,3 ---	1,2,7-9, 14-18, 20-22
X	CYDULKA R K ET AL: "EFFECTS OF COMBINED TREATMENT WITH GLYCOPYRROLATE AND ALBUTEROL IN ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE" ANNALS OF EMERGENCY MEDICINE, LANSING, MI, US, vol. 25, April 1995 (1995-04), pages 470-473, XP000979833 ISSN: 0196-0644 the whole document --- -/--	1,2,8, 13-17, 20-22

1

INTERNATIONAL SEARCH REPORT

Interr ɔnal Application No
PCT/GB 01/01606

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
X	HADDAD E-B ET AL: "PHARMACOLOGICAL CHARACTERIZATION OF THE MUSCARINIC RECEPTOR ANTAGONIST, GLYCOPYRROLATE, IN HUMAN AND GUINEA-PIG AIRWAYS" BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 127, no. 2, 1999, pages 413-420, XP000979853 ISSN: 0007-1188 abstract	1,2, 8-10, 13-17, 20-22
X	WO 98 34595 A (HERZOG KURT ;JAGO PHARMA AG (CH); KELLER MANFRED (DE)) 13 August 1998 (1998-08-13) abstract page 4, line 24 -page 7, line 13 page 16, line 5-8; examples 1-7	23-28
X	WO 00 06121 A (HERZOG KURT ;JAGO RES AG (CH); KRAUS HOLGER (CH); MUELLER WALZ RUD) 10 February 2000 (2000-02-10) abstract; claims 20,21,24; example 3	1,23-28
X	WO 00 07567 A (HERZOG KURT ;JAGO RES AG (CH); KRAUS HOLGER (CH); MUELLER WALZ RUD) 17 February 2000 (2000-02-17) abstract; examples 3-5,7,8,13	1,12, 23-28
A	WO 97 39758 A (KENNEDY THOMAS P) 30 October 1997 (1997-10-30) abstract page 16, line 35 -page 17, line 11 page 22, line 26 -page 23, line 4	1-24

1

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1,3-25,27,28,30-31 relate to a compound/use defined by reference to a desirable characteristic or property, namely antimuscarinic agent, hydrophobic matrix material, beta2 agonist, mucolytics, MMPi, antibiotic, antineoplastic, vaccine, antitussive, PDE4 inhibitor, elastase inhibitor.

The claims cover all compounds/uses having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds/uses. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds/uses by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Present claims 1,3-25,27,28,30-31 relate to an extremely large number of possible compounds/uses as far as relating to steroids, Leucotrienes, peptides. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds/products/apparatus/methods claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds/uses specifically claimed (glycopyrrolate in combination with magnesium stearate, ipratropium, tiotropium).

Remark: Claim 10 is not clear because it depends on claim 10. This claim was searched as depending on claim 2.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

ormation on patent family members

Interr ›nal Application No
PCT/GB 01/01606

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 0028979	A	25-05-2000	AU	6457899 A	05-06-2000
			WO	0028979 A1	25-05-2000
			CN	1326341 T	12-12-2001
			EP	1131059 A1	12-09-2001
			NO	20012346 A	26-06-2001
US 5612053	A	18-03-1997	AU	712369 B2	04-11-1999
			AU	5391796 A	23-10-1996
			CA	2216828 A1	10-10-1996
			EP	0818991 A1	21-01-1998
			HU	9802828 A2	28-07-1999
			JP	11501937 T	16-02-1999
			NO	974404 A	23-09-1997
			NZ	305800 A	26-08-1998
			WO	9631198 A1	10-10-1996
			US	5738865 A	14-04-1998
WO 9834595	A	13-08-1998	AU	718967 B2	04-05-2000
			AU	5649698 A	26-08-1998
			WO	9834595 A1	13-08-1998
			EP	1014943 A1	05-07-2000
			JP	2001511160 T	07-08-2001
			NO	993773 A	04-10-1999
			ZA	9800937 A	06-08-1998
WO 0006121	A	10-02-2000	AU	4598999 A	21-02-2000
			WO	0006121 A1	10-02-2000
			CN	1312706 T	12-09-2001
			EP	1100465 A1	23-05-2001
			NO	20010391 A	23-03-2001
WO 0007567	A	17-02-2000	AU	4893999 A	28-02-2000
			WO	0007567 A1	17-02-2000
			CN	1315852 T	03-10-2001
			EP	1102579 A1	30-05-2001
			NO	20010531 A	31-01-2001
WO 9739758	A	30-10-1997	US	5849263 A	15-12-1998
			AU	2809697 A	12-11-1997
			CA	2251656 A1	30-10-1997
			EP	0910390 A1	28-04-1999
			JP	2001504438 T	03-04-2001
			WO	9739758 A1	30-10-1997
			US	6165445 A	26-12-2000